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The role of angiogenesis in acute leukaemia has been discussed since the cloning of the gene of vascular endothelial growth factor
(VEGF) from the acute myelogenous leukemia cell line (HL60) and, thereafter, when the ﬁrst studies reported increased bone
marrow vascularity and elevation of angiogenic cytokines in acute lymphoblastic leukaemia (ALL). VEGF and basic ﬁbroblast
growth factor (bFGF) are the major proangiogenic cytokines that have been studied, and evaluation of their prognostic impact in
childhood ALL has been reported in several studies, though with controversial results. The antiangiogenic response, contributing
to the angiogenic balance, has scarcely been reported. The origin of the factors, their prognostic value, and their relevance as good
markers of what really happens in the bone marrow are discussed in this paper. The place of antiangiogenic drugs in ALL has to be
deﬁned in the global treatment strategy.
1.AngiogenesisinHematological Malignancies
Angiogenesis is a highly regulated process balanced by
inhibitors and stimulators of endothelial cell prolifera-
tion, endothelial cell migration, and capillary formation
molecules. Cancer cells begin to promote angiogenesis early
in tumorigenesis. This angiogenic switch is promoted by
oncogene-driven tumor expression of proangiogenic pro-
teins. The key mediator of angiogenesis is a proangiogenic
factor,thevascularendothelialgrowthfactor (VEGF).VEGFis
a homodimeric glycoprotein which stimulates angiogenesis
and vascular permeability by interacting with the tyrosine
kinase receptor 2 (VEGFR-2 or KDR/Flk-1) and 1 (VEGFR-
1 or Flt-1) [1]. These receptors belong to the superfamily
of receptor tyrosine kinases (RTKs) and share a common
structure with a single transmembrane domain. The central
role of the VEGF-R2 in angiogenesis in general and in the
development of solid tumors in particular has been widely
demonstrated,anditisnowconsideredasthemainmediator
of VEGFA eﬀect on endothelial cells. Its interaction with
VEGF is enhanced by neuropilin-1, which, thereby, has
been proposed as a potential target to inhibit VEGF-driven
angiogenesis [2].
One other major factor involved is the basic ﬁbroblast
growth factor (bFGF), a member of the FGF family of
proteins, which interacts with tyrosine kinase receptors
(FGFR-1 or FGFR-2) to exert mitogenic eﬀects on endothe-
lial, ectoderm-, and mesoderm-derived cells. Beyond its
mitogenic activity, bFGF acts synergistically with VEGF in
the angiogenic switch [3]. VEGF-A and bFGF are both
major stimulators of angiogenesis that are commonly found
in malignant tumors. Many other factors are involved in
this physiological process and can balance the eﬀects of
these major activators of angiogenesis, such as the angiopoi-
etin family [4], endothelins, or adipokines, which are all
expressed in the bone marrow (for a review, see [5]).
It is now well established that solid tumors progress
in concert with an induction of tumor angiogenesis which
is fundamental for tumor growth and spread. In adults,
the physiological angiogenesis is limited to a few speciﬁc
processes such as wound healing, tissue repair, and the
female reproductive cycle [6]. The work of Folkman led
to the recognition that angiogenesis plays a major role in
tumor development, progression, and metastasis [7]. There
is emerging evidence that angiogenesis plays a role in the
physiopathologyofhematologicalmalignanciesaswell[8,9].2 Advances in Hematology
Leukemias have been associated with angiogenesis since
the acute myeloid leukaemia (AML) cell line HL60 was ﬁrst
used to clone the VEGF gene. High microvessel density
in acute leukemias, presence of receptors to proangiogenic
factors on leukemic cell lines, and some evidence of prog-
nostic impact of plasmatic levels of VEGF in AML [10]
are convincing arguments of the impact of angiogenesis in
leukemogenesis.
Beside the direct eﬀect of angiogenic factors on endothe-
lial cells, autocrine and paracrine VEGF/VEGF-related loops
were described in hematological malignancies such as acute
and chronic leukaemia, myelodysplastic syndromes (MDS),
myeloproliferative neoplasms, lymphomas, and multiple
myeloma [11]. Recently, neuropilin-1 expression was found
increased in the bone marrow of AML and ALL patients
when compared to control specimens [12]. It has been
d e s c r i b e di ns e v e r a lm e d u l l a rc e l ltyp e sa sw e l la si nl e u k e m i c
cell lines [12] and thus may modulate the VEGF autocrine
loop that enhances survival of leukemic cells [13]. Though,
it remains diﬃcult to establish a clear relation between intra-
medullary vascularisation and the expression of angiogenic
factors.
2. Angiogenesisin Childhood Acute
Lymphoblastic Leukaemia
Increased bone marrow vascularity has been reported in
chronic and acute leukaemia of myeloid and lymphoid
lineages in adults [14–16]. In adult ALL as well, some studies
show the role of angiogenesis [14, 17]. In childhood ALL, the
published studies are scarce [18, 19].
The ﬁrst study demonstrating that childhood ALL pro-
gression might be accompanied by an increase of bone
marrow vascularisation was published by Perez-Atayde
et al. [20]. They demonstrated that the bone marrow of
these children had increased blood vessel content compared
to normal counterparts, suggesting that leukemia might be
angiogenesis dependent and raising the possibility for a
role of antiangiogenic therapy in the treatment of leukemia.
Detailed analysis of bone marrow sections from ALL patients
ledtothedevelopmentofamodeltoillustratetheirirregular,
albeit abundant, bone marrow vasculature. After this pilot
study, the degree of angiogenesis was quantiﬁed either by
measuring microvessel density (MVD) in bone marrow
biopsies or by iron oxide-enhanced magnetic resonance
imaging and was found to be increased in both acute and
chronic leukemias [18, 21, 22].
3.Which Relevant Markers for Intramedullary
AngiogenesisEvaluation?
Concerning intramedullary angiogenesis, two types of inves-
tigations are performed, either on BM biopsies or in
ﬂuid samples, that is, urines plasma, or serum. Among
the huge variety of angiogenic markers already identiﬁed,
discrepancies between the conclusions of published studies
were evidenced.
Beside the evaluation of MVD, the work of Perez-Atayde
et al. also established that high levels of urinary bFGF were
found in all children with newly diagnosed ALL, compared
to nonleukemic controls [20]. Several studies have, since
then, investigated the protein levels of VEGF and bFGF on
diﬀerent ﬂuids [19, 26, 30]. Others have analysed VEGF-
A mRNA levels in bone marrow samples both at diagnosis
and at relapse using reverse transcription polymerase chain
reaction (RT-PCR) techniques [24, 27]. In all these reports
the number of patients was low, and controversial results
werefound(Table 1).IncontrasttothestudyofPerez-Atayde
et al., we observed elevated levels of urinary bFGF only in
54% of patients.
These discrepancies between the diﬀerent studies could
be related to the heterogeneity of the samples analysed: some
were performed on serum which contains higher amounts
of angiogenic factors than plasma, because of the storage
of these molecules in platelets, such as VEGF or endostatin
[23, 32]. In addition, circadian variations of angiogenic
factors, especially endostatin, were described and have to be
considered [33].
Beside its physiological relevance in the angiogenic
process, the noninvasive method of detecting urinary levels
of this molecule by an ELISA method on urinary samples
made it easy to study on patients, especially in children.
In the same way, studies in plasma or serum of angiogenic
factors are made on samples collected for usual clinical
practice and do not require additional samples. In the
countries where no bone marrow biopsies are performed at
diagnosisofchildhoodacuteleukaemia,diagnosisismadeon
bone marrow aspirates. Therefore, it does not seem ethical to
perform these biopsies which are invasive. But an important
question arises concerning the reliability of measures of
angiogenic or antiangiogenic factors: is this indirect way of
measuring bone marrow angiogenesis a good reﬂect of the
physiology of angiogenesis in leukemogenesis?
A part of the answer can be given by the study published
in 2006 by Veiga et al. who reported their results on BM
plasma from ALL patients. They screened BM plasma for
VEGF and bFGF by a competitive ELISA method. Similarly
to our results on urine samples, they observed that the BM
plasma contained elevated levels of bFGF in 58% of ALL
patients compared to the BM plasma of normal donors
(P<0.05). In contrast, the mean levels of VEGF did not
signiﬁcantly diﬀer between leukemic and normal BM plasma
(P>0.1) [34]. These resultsshow that, in a majority of cases,
the leukemic BM plasma contained increased levels of bFGF,
extending the observations of high bFGF levels in urine or
plasma [14, 26]
We previously reported about higher median levels of
urinary bFGF in patients than in healthy controls [25].
Interestingly bFGF levels were lower for patients with a bad
outcome (relapse or death). This work was extended to a
larger number of patients and included measures of urinary
VEGF levels which were not higher in patients than controls,
buthighlevelsofVEGFindicatedpoorprognosiswithahigh
relapse rate [26].
The angiogenic response in children with ALL is actually
demonstrated. The limits of the various studies remain thatAdvances in Hematology 3
Table 1: Main studies concerning the prognostic value of bFGF and VEGF in adult (A) and childhood (C) ALL.
Authors, journal, and
publication year N. patients Type of samples Measured criteria Prognostic value
Aguayo et al. Blood, 2000
[14] A:28 BM [20] and Plasma
[23] (diagnosis)
MVD and plasmatic
levels of VEGF and bFGF
Not determined.
  MVD; no high levels
of VEGF in LAL
Koomagi et al., Clin
Cancer Res, 2001 [24] C:53 BM (RT-PCR), diagnosis
[25], relapse [22] VEGF levels, outcome
  VEGF correlated to
better overall survival
Yetgin et al., Leukemia
Lymphoma, 2001 [19] C:31 Serum (VEGF & bFGF)
(diagnosis and CR)
Correlations with
prognosis criteria
( H M G ,W B C ,H b ,
platelets, phenotype)
Positive correlation, only
with platelets
Pul` e et al., Br J Hematol,
2002 [18] C:41 BM (diagnosis and CR)
MVD & correlations
with outcome (relapse)
and prognosis criteria
( a g e ,s e x ,c y t o g e n e t i c s ,
phenotype)
No correlation
Schneider et al., Br J
Hematol, 2003 [26] C:39 Urine (diagnosis)
Levels of urinary bFGF
a n dV E G Fl e v e l s&
outcome
  bFGF and/or   VEGF
signiﬁcantly associated
with poor outcome
Wellmann et al.,
Leukemia, 2004 [27]
C:18
C: 6
BM (diagnosis)
Plasma (relapse)
Expression of VEGF &
VEGF-R & HIF-1α by
immunostaining;
RT-PCR on
BM-extracted RNA
 VEGF and HIF-1α
shorter DFS
 VEGF if treatment
resistance (MRD+)
Faderl et al. Blood, 2005
[17] A:95 Plasma (diagnosis)
Relative risk of death
(RR) according to VEGF
levels
RR of death ×8i fV E G F
<19.1pg/mL
Avramis et al., Clinic
Cancer Res, 2006 [28] C: 17 Serum (diagnosis, d14,
d28)
Evolution of VEGF levels
during induction;
correlation with EFS
Positive predictive value
of relapse if   VEGF
Schneider et al.,L e u k
Res, 2007 [29] C:33 Urine and plasma
(diagnosis, relapse)
Levels of endostatin,
bFGF, VEGF
  plasma VEGF at
relapse
No prognostic value of
endostatin levels
Lyu et al., Yonsei Med J,
2007 [30] C:33 BM Plasma (diagnosis
and relapse)
Levels of VEGF & bFGF,
correlations with WBC
and age
Higher bFGF and VEGF
levels in relapse. No
correlations
Stachel et al., Oncology
Reports, 2007 [31] C:46 BM (diagnosis)
RT-PCR on
BM-extracted RNA;
correlations with relapse
and survival
  VEGF correlated to
late relapse
BM:bonemarrow;MVD:microvesseldensity;C:children;A:adults;D:atdiagnosis;CR:completeremission;RR:relativerisk;EFS:event-freesurvival;bFGF:
basic ﬁbroblast growth factor; VEGF: vascular endothelial growth factor; HIF-1α: subunit 1α of hypoxia-induced factor 1; MRD: minimal residual disease.
they hardly reﬂect the complexity of the in vivo balance of
pro- and antiangiogenic cytokines interacting as a whole
process. If the role of proangiogenic factors is documented,
less is known about the antiangiogenic response. Endostatin
is a fragment of collagen XVIII having anti angiogenic eﬀect
throughantimigratoryandanti-proliferativeproperties[35].
In a previous work we focused our attention on endostatin
in childhood ALL and observed that the median serum
level of endostatin was signiﬁcantly higher in patients than
controlatdiagnosis aswellasin remission. The highest levels
were observed in patients with a hyperdiploid karyotype.
It is interesting to note that collagen XVIII is mapped
to chromosome 21. Thereby, the possible duplication of
chromosome 21 in patients with a hyperdiploid karyotype
could explain our results [29]. In contrast to urinary levels of
bFGF and VEGF, no prognostic value of plasma endostatin
can yet be considered. To our knowledge, no other study
concerning antiangiogenic factors and childhood ALL has
been published since.
4.PrognosticValue of These Factors
The ﬁrst results concerning the prognostic value of angio-
genic factors were reported in AML adult patients, showing
that high levels of cellular VEGF were signiﬁcantly correlated
with shorter survival in patients with high WBC at diagnosis4 Advances in Hematology
(P<0.04), whereas no association was found with the
plasma levels of bFGF [10]. In B-cell chronic lymphocytic
leukaemia, serum levels of VEGF correlated positively with
biological markers of prognostic relevance such as ZAP-
70 expression, CD38 expression and mutational status of
IgVH. In this study high circulating VEGF levels reﬂected an
aggressive biological proﬁle [36].
Controversial results were found concerning the asso-
ciation of VEGF or bFGF with usual prognostic factors of
ALL and the outcome of patients (Table 1). One of the
pediatric studies was performed on 31 children with newly
diagnosed ALL and on 22 patients at relapse. Signiﬁcantly
higher VEGF levels were found in patients at relapse, and
lower VEGF levels at diagnosis were associated with a longer
overall survival [24]. In another study, serum levels of VEGF
and bFGF were compared in a group of 31 children with
ALL at diagnosis and then in complete remission (CR). The
authors reported higher VEGF levels in CR than at diagnosis
(26 children/31), suggesting that VEGF could increase when
normal hematopoiesis is restored [19].
In a series of children with ALL, we found a correlation
between usual poor prognostic features and the interactions
between leukemic cells and BM environment. Twenty-three
B-lineage ALLs at diagnosis were studied for the urinary
secretion of bFGF and VEGF. The levels of bFGF were
markedly elevated in ALL children versus controls (median
460 versus 30pg/mmol creatinine, respectively, P<0.01)
but lower for patients with poor prognostic features. In this
population there was a signiﬁcant relation between normal
levels of bFGF and high-risk factors (P = 0.027). In the same
population, median value of VEGF was higher for patients
than controls, but without statistic diﬀerence. We cultured
leukemic cells with and without ﬁbroblasts and observed a
reduction of apoptosis rate (annexine V test), especially in
patients with high urinary bFGF levels. Among the patients
with a bFGF level within the normal range, most show
no inﬂuence of ﬁbroblasts on apoptosis, suggesting that a
subset of highly proliferative leukemias could have a growth
independent of the medullary stroma [25].
The role and inﬂuence of medullary stroma has been
stressed out in a recent study by Nor´ en-Nystr¨ om et al.
where MVD was analysed at diagnosis in large series of 185
patients. Correlations were found between higher MVD and
some speciﬁc biological features: T-ALL phenotype, high-
hyperdiploidleukemia,andhighWBCcountinB-ALL.They
also showed that B-ALL patients had a worse outcome when
having high MVD and high marrow reticulin ﬁbre density
[37].
5. Originof the Angiogenic Factors
The angiogenic cytokines can be produced by leukemic
and/or bone marrow (BM) microenvironmental cells.
In a previous work we focused on the origin of pro- and
antiangiogenic factors (bFGF, VEGF, endostatin) in patients,
trying to identify whether they originate from lymphoblasts
or not. Lymphoblast mRNA expression (RT-PCR) has
shown that VEGF and endostatin partially originate from
Table 2:Expressionofendostatin,vascularendothelialgrowthfactor
(VEGF), and basic ﬁbroblast growth factor (bFGF) by lymphoblasts
(RT-PCR) in a group of 24 patients. The protein was measured by
ELISA method in 28 patients and was expressed in half of the cases
studied, for endostatin and VEGF. We found no expression of bFGF
by the lymphoblasts, neither bFGF mRNA nor protein expression
[29].
mRNA (RT-PCR) Protein (ELISA)
Endostatin 19/24 14/28
VEGF 24/24 6/12
bFGF 0 0
lymphoblasts, whereas bFGF seems to have a stromal origin.
Quantiﬁcationinthesupernatantoflymphoblastsconﬁrmed
these ﬁndings in half of the cases studied (Table 2). In a
recent work using protein microarrays, we observed that
the supernatants of puriﬁed lymphoblasts contain only a
limited number of angiogenic factors. In a series of patients
we found a signiﬁcant expression, of insulin growth-factor
binding protein 2 (IGFBP-2), interleukin-8 (IL8) but also of
thematrixmetalloprotease-9(MMP-9)anditsinhibitortissue
inhibitor of MMP -1 (TIMP-1) (unpublished data).
Therefore, the interaction between leukemic cells and
microenvironment is certainly determinant in the pro-
duction of angiogenic factors. Veiga et al. have shown a
contact-dependent interaction between ALL cells of patients
and BM endothelium in presence of angiogenic cytokines.
This interaction leads to the survival of leukemic cells by
maintaining the expression of antiapoptotic genes [38].
The BM microenvironment contains ﬁbroblasts, adipo-
cytes, osteoblasts, in addition to endothelial and hema-
topoietic cells, which all may interact with leukemic cells
and modulate ALL progression. Matrix metalloproteases
(MMPs) are a family of zinc-dependent neutral endopep-
tidases involved in physiological proteolytic degradation of
various components of the extracellular matrix which is an
important source of pro- and antiangiogenic factors [39].
They participate to the crosstalks between leukemic and
stromal cells (Figure 1). We observed that a high secretion
of MMP-9 is associated with a poor prognosis in childhood
ALL, but there was no direct correlation between the
secretion of MMP-9 and urinary bFGF or VEGF [40].
In a study by Suminoe et al., ratios of MMP-mRNAs
and TIMPs-mRNAs have been established, and there is a
positive correlation between these ratios and the invasivity
of leukemic cells, showing the possible role of MMPs in ALL
progression [41].
6. To a Better Knowledge of Leukemia
Angiogenesis: Inﬂuence of Hypoxia
In solid tumors, it is known that local hypoxia induces
transcriptional regulators, the most prominent of which
appears to be hypoxia-induced factor 1 (HIF-1). It has
been demonstrated that hypoxia (about 6% oxygen partial
pressure) exists in normal marrows [42]a sw e l la si nm a rr o wAdvances in Hematology 5
HIF
VEGF
VEGF
VEGF
Survival
ANG
Lymphoblast
Fibroblast
bFGF
bFGF
MMP
MMP
Hypoxia
Endothelial cells
bFGF
ANG
bFGF
Crosstalk
ES
ES
ES
Fibrillar stroma
bFGF
Figure 1:Interactionsbetweenleukemiccells(lymphoblasts)andsomeoftheBMcomponents.Leukemiccellsandendothelialcellsproduce
vascular endothelialgrowthfactor (VEGF),andbasic ﬁbroblast growth factor (bFGF) is produced by ﬁbroblasts. VEGF plays akey role in vessel
growth but also in blood vessel survival. Through its autocrine loop, VEGF enhances lymphoblast survival. The matrix metalloproteases
secretedbylymphoblastsdegradetheextracellularmatrixandliberategrowthfactorssuchasbFGF.Hypoxiainduces,viatheHIF-1αsubunit,
the expression not only of VEGF but also of angiopoietin 2 (ANG). Endostatin (ES) is expressed by leukemic and stromal cells.
from patients suﬀering from acute myeloid leukemia [43]. In
addition, the HIF-1α subunit is overexpressed in leukemic
cell clusters within the bone marrow of children suﬀering
from ALL [27]. Thus, studies on the role of ALL cells in
the induction or maintenance of bone marrow angiogenesis
may lack physiologic relevance when performed in standard
culture conditions (under 21% O2).
For this reason, we developed an in vitro model to
study of the role of reduced oxygen conditions on the
interactions between ALL cells and bone marrow endothelial
cells. We used the human pre-B-lymphoblastic Nalm-6 cell
line. Cells were cultured either in a conventional incubator,
for example, under 21% oxygen pressure and 5% carbon
dioxide (normoxic condition), or in a hypoxia chamber with
low-oxygen air that contained 5% oxygen and 5% carbon
dioxide (hypoxic condition).
The pattern of angiogenic factors secreted by Nalm-
6 cells in normoxic condition was very similar to that
observed in cells from patient bone marrow, except that
Nalm6 cells do not secrete detectable levels of interleukin-8.
Comparison of supernatants from Nalm6 cells in normoxic
and hypoxic condition allowed us to identify 3 groups of
cytokines: (1) proteins whose secretion was not modiﬁed
by hypoxia, (2) proteins whose secretion was enhanced
by hypoxia, and (3) proteins that were not detectable in
supernatants from normoxic condition and were detected in
those from hypoxic condition. This model is certainly closer
to physiopathological conditions and could help to have a
better understanding of the role of each angiogenic factor.
7. Place of AntiangiogenicTherapies inthe
Global Strategy of ALL Treatment
Chemotherapy treatment intensity in childhood ALL is
reaching its upper limits regarding induced toxicity versus
beneﬁt for the patient, in particular for high-risk patients.
Over the past decades, outcome of these patients has widely
improved, especially in standard risk groups. Though, high-
risk patients and some refractory patients to regular treat-
ment still need new therapeutic approaches. Antiangiogenic
drugs are already used in clinical practice for the treatment
of metastatic breast cancer and advanced or metastatic renal
tumors and show interesting results in association with
conventional therapy [44]. In haematological malignancies,
the use of thalidomide in multiple myeloma is one of the
pioneers in antiangiogenic treatments [45]. Some antian-
giogenic drugs have been suggested as a supplementary
treatment alternative in acute leukaemia, and new drugs are
presently under investigation in clinical trials in refractory
AML (NCI clinical trials). But the place of these treatments
still has to be deﬁned. In a feasibility study, bevacizumab
(Avastin, Genetech) was administered to adult patients with
refractory AML and resulted in modest clinical beneﬁt [46].6 Advances in Hematology
In our work concerning childhood ALL, we found an
association between normal bFGF levels and poor outcome
suggesting that some proliferative forms of leukaemia may
proliferate without the inﬂuence of stromal microenvi-
ronnement [25]. On the other hand, VEGF levels are
signiﬁcantly increased for relapsing patients, showing that
angiogenic factors are diﬀerently involved in the evolution of
the disease [26]. In a risk-adapted strategy, it is still necessary
to deﬁne properly which group of children will beneﬁt from
these new agents. As an example, Nor´ en-Nystr¨ om et al.
have identiﬁed some biological subgroups of childhood ALL
patients, like T-ALL which are usually more aggressive forms
of ALL, with high MVD scores [37]. They suggest that these
subgroups should probably be the ﬁrst to be considered for
antiangiogenic therapies.
Besidedirecteﬀectofantiangiogenicdrugs,theautocrine
loop of VEGF enhances survival of leukemic cells and
might be an interesting target for anti-VEGF molecules, that
is, in aggressive forms of childhood ALL. Moreover, one
must point out that targeting VEGF-A sometimes results in
adaptative resistance as it has been observed in solid tumors
[47]. Drug development targeting other angiogenic factors
such as the angiopoietin-Tie2 pathway [48] or preventing
the interaction between leukemic cells and endothelium [49]
may oﬀer new therapeutic combinations to improve clinical
responses.
8. Conclusions
Targeting VEGF is perhaps an interesting treatment strategy,
not only for the inhibition of angiogenesis but to disrupt the
autocrine loop associated with the survival and invasivity of
leukemic cells. Indeed it has been shown that VEGF induce
the secretion of MMP-2 and MMP-9 which contribute to
the lymphoblasts invasivity [13]. We also demonstrated that
secretion of MMP-9 is a poor prognostic factor in childhood
ALL [40]. Therefore, inhibition of VEGF could be of
potential interest to limit aggressivity of proliferative forms
of childhood ALL. In agreement with this hypothesis, it was
shownthatsomeVEGFpolymorphismswereassociatedwith
high risk of relapse in ALL children [50]. However, it was not
precised in this work if these polymorphisms were associated
withdiﬀerent levels of MVD or independent of angiogenesis.
At least at this time our knowledge of angiogenic process
in childhood ALL remains poorly understood. It remains
unclear which parameter is the most relevant as angiogenic
marker and which sample (BM, urine, plasma, or serum)
should be analysed. Most of the studies focused on bFGF
and VEGF, but many other angiogenic factors can modu-
late bone marrow vascularisation. In other haematological
malignancies, VEGF receptors have been widely explored,
and the role of angiopoietin-2 has been clearly identiﬁed in
AML [51]. At this time, the analysis of factors one by one is
not a satisfying approach, and global strategies are needed,
such as proteomic and genomic methodologies.
Considering the low incidence of childhood ALL, mul-
ticentric studies are mandatory to analyse the inﬂuence of
angiogenesis in leukemogenesis and the potential interest of
angiogenic therapies.
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